Clinical and microbiological characteristics of pneumonia in immunocompromised hosts: a prospective observational study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400084802

Enrollment

Unknown

Registered

2024-05-24

Start date

2024-06-01

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

immunocompromised host pneumoni

Interventions

Observations:No

Eligibility

Sex/Gender

All

Age

18 Years to 88 Years

Inclusion criteria

Inclusion criteria: 1) immunocompromised patients; 2) diagnosis of pulmonary infection; 3) mNGS sequencing, culture, multiplex PCR, GM detection and microecology detection of BALF or sputum have been completed; 4) Biochemical tests such as blood routine, liver and kidney electricity, disseminated intravascular coagulation, lymphocyte subsets, cytokines and blood G test have been completed; 5) provide written informed consent

Exclusion criteria

Exclusion criteria: 1) less than 18 years old; 2) the interval between last discharge and current admission was less than 48 days; 3) clinicians consider non-infectious interstitial lung disease, atelectasis, pulmonary embolism, and other diseases leading to related lung changes or symptoms; 4)) other concurrent infections; 5) pregnant or breastfeeding; 6) unable to complete the follow-up survey.

Design outcomes

Primary

Measure	Time frame
etiology;Basic information and medical history;red?blood?cell?count;Hemoglobin;Hematocrit;platelet;white blood cell;neutrophil count;lymphocyte count;monocyte count;eosinophil count;basophil count;Activated Partial Thromboplastin Time;Prothrombin Time;fibrinogen;international normalized ratio;D-dimer;total bilirubin;alanine aminotransferase;aspartate aminotransferase;alkaline phosphatase;glutaminyl cyclotransferase ;albumin;serum creatinine;blood urea nitrogen;uric acid;sodium ion;potassium ions;fasting blood glucose;lactate dehydrogenase;Interleukin 2;Interleukin 4;Interleukin 6;Interleukin 10;tumour necrosis factor a;interferon ?;CD3+ cells occupy lymphatic system ;CD3+CD4+ cells occupy lymphatic system;CD3+CD8+ cells occupy lymphatic system;CD19+ cells occupy lymphatic system;CD16+CD56+CD3-NK cells occupy lymphatic system;CD3+ cells absolute count;CD3+CD4+ cells absolute count;CD3+CD8+ cells absolute count;CD19+ cells absolute count;CD16+CD56+CD3-NK cells absolute count;G test;GM test;Metagenomic Next-Generation Sequencing;	—

Measure

Time frame

etiology;Basic information and medical history;red?blood?cell?count;Hemoglobin;Hematocrit;platelet;white blood cell;neutrophil count;lymphocyte count;monocyte count;eosinophil count;basophil count;Activated Partial Thromboplastin Time;Prothrombin Time;fibrinogen;international normalized ratio;D-dimer;total bilirubin;alanine aminotransferase;aspartate aminotransferase;alkaline phosphatase;glutaminyl cyclotransferase ;albumin;serum creatinine;blood urea nitrogen;uric acid;sodium ion;potassium ions;fasting blood glucose;lactate dehydrogenase;Interleukin 2;Interleukin 4;Interleukin 6;Interleukin 10;tumour necrosis factor a;interferon ?;CD3+ cells occupy lymphatic system ;CD3+CD4+ cells occupy lymphatic system;CD3+CD8+ cells occupy lymphatic system;CD19+ cells occupy lymphatic system;CD16+CD56+CD3-NK cells occupy lymphatic system;CD3+ cells absolute count;CD3+CD4+ cells absolute count;CD3+CD8+ cells absolute count;CD19+ cells absolute count;CD16+CD56+CD3-NK cells absolute count;G test;GM test;Metagenomic Next-Generation Sequencing;

—

Secondary

Measure	Time frame
arteries and blood;chloride ions;calcium ions;C-reactive protein;procalcitonin;	—

Countries

China

Contacts

Public ContactYuan Yin

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

799101915@qq.com+86 138 7107 4119

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026